Adjusted gross margin is expected to land between 45% and 47%. Adjusted EBITDA is anticipated to be between $135 million to $155 million. Net income is expected to be between a loss of $30 million and ...
Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease, which ...
BioMarin Pharmaceutical (NASDAQ:BMRN) introduced its longer-term outlook and plans to implement a $500M cost transformation program at its investor day event today. The California-based pharma has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results